- Rheumatologie-App Injektionstechnik
- Neue Studien
- Kongress Highlights
- EULAR 2019
- EULAR 2018
- EULAR 2017
- EULAR 2016
- EULAR 2015
- EULAR 2014
- ACR 2019
- ACR 2018
- ACR 2017
- ACR 2015
- ACR 2014
- Rheuma Top 2019
- Rheuma Top 2018
- Rheuma Top 2017
- Rheuma Top 2015
- Rheuma Top 2014
- Bilddatenbank
- RheumaTool
- SlideSet RA
- SlideSetSpA
- SonoTool
- FOCUS «Der Fuss»
- FOCUS «Die Hand»
- FOCUS «Kinderrheumatologie»
- EisenPaket
- LupusPaket
- OsteoPaket
- Publikationen
- Literaturservice
- Richtlinien
- Schmerzpaket
- Immunotalk
EULAR 2018 | Daily Highlights
Antibodies in FMS
EVALUATION OF TISSUE SPECIFIC AUTOANTIBODIES IN FIBROMYALGIA PATIENTS WITH SICCA AND/OR XEROSTOMIA
Abstract: THU0508
Authors: E. Applbaum, A. Lichtbroun
Key content:
This study aimed to examine the relationship between SS and fibromyalgia by testing patients with fibromyalgia, that also complain of xerostomia and sicca symptoms for Sjögren’s related autoantibodies SSA/Ro, SSB/La and the recently described Sjögren related tissue specific antibodies (TSA) against salivary gland protein 1 (SP-1), carbonic anhydrase 6 (CA6) and parotid secretory protein (PSP).
Patients that presented with symptoms of fibromyalgia and fulfilled both the 1990 and 2010 preliminary diagnostic criteria and complained of sicca symptoms were evaluated. Only patients who had the following criterias: Using artificial tears at least biweekly, drinking water excessively to relieve dry mouth, or have previously experienced a blocked tear duct, but did not meet the diagnostic criteria for SS and did not have elevated inflammatory markers ESR or CRP, were selected for this study. In this study population Sjögren’s related biomarkers SSA/Ro, SSB/La, SP-1, CA6, and PSP were measured.
From the 310 patients fulfilling the above criteria about 1/3 were tested positive for one or more of the TSAs (SP-1, CA6, PSP) and classic Sjögren’s markers (SSA/Ro, SSB/La), with the majority of those patients being positive for one or more of the TSAs.
Relevance:
This study implicates that patients with fibromyalgia and sicca symptoms should be thoroughly examined for underlying Sjögren’s disease.

Zusammenfassung und Kommentar von:
Dr. Thomas Langenegger
Zug